Christal Mickle
Founder at ZEVRA THERAPEUTICS, INC.
Net worth: 772 508 $ as of 2024-03-30
Profile
Christal M.
M.
Mickle is the founder and the Chief Development Officer at Zevra Therapeutics, Inc., a company founded in 2006.
Prior to her current position, she worked as a Research Associate at New River Pharmaceuticals, Inc. from 2002 to 2005.
Ms. Mickle holds a graduate degree from the University of Virginia, which was conferred in 2005, and an undergraduate degree from Virginia Polytechnic Institute & State University, which was conferred in 2001.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
0.32% | 2024-03-21 | 133,191 ( 0.32% ) | 772 508 $ | 2024-03-30 |
Christal Mickle active positions
| Companies | Position | Start |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Founder | 2006-10-29 |
Former positions of Christal Mickle
| Companies | Position | End |
|---|---|---|
New River Pharmaceuticals, Inc.
 New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Corporate Officer/Principal | 2004-12-31 |
Training of Christal Mickle
| University of Virginia | Graduate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Health Technology |
- Stock Market
- Insiders
- Christal Mickle
